Dopamine β-monooxygenase: Mechanism, substrates and inhibitors

Current Enzyme Inhibition

Volumn 5, Issue 1, 2009, Pages 27-43

  Beliaev, Alexandre ^a   Ferreira, Humberto ^a   Learmonth, David A ^a   Soares da Silva, Patrício ^a  

^a DEPARTMENT OF RESEARCH AND DEVELOPMENT   (Portugal)

Author keywords

BIA 5 453; CHF; Dopamine hydroxylase; Dopamine monooxygenase; Imidazolethione; Inhibitor; Nepicastat

Indexed keywords

1 (2 THIOPHEN 2 YLETHYL) 1,3 DIHYDROIMIDAZOLE 2 THIONE; 1 (3,5 DIFLUORO 4 HYDROXYBENZYL) 1,3 DIHYDROIMIDAZOLE 2 THIONE; 1 (3,5 DIFLUOROBENZYL) 1,3 DIHYDROBENZOIMIDAZOLE 2 THIONE; 1 (3,5 DIFLUOROBENZYL) 1,3 DIHYDROIMIDAZOLE 2 THIONE; 1 (3,5 DIFLUOROBENZYL)IMIDAZOLINE 2 THIONE; 1 (4 HYDROXYBENZYL) 1,3 DIHYDROIMIDAZOLE 2 THIONE; 1 BENZYL 1,3 DIHYDROIMIDAZOLE 2 THIONE; 1 PHENYL 3 (2 THIAZOLYL)THIOUREA; 1 PHENYL 3 THIAZOL 2 YLTHIOUREA; 1 THIOPHEN 2 YLMETHYL 1,3 DIHYDROIMIDAZOLE 2 THIONE; 2 (2 BENZIMIDAZOLYL)AMINO 2 IMIDAZOLINE; 2 PHENYLSULFANYLETHYLAMINE; 3 (3,5 DIFLUOROBENZYL) 1 H PYRIDINE 2 THIONE; 3 (N METHYLHYDRAZINOMETHYL)PHENOL; 3 HYDROXY 4 PHENYL 3H THIAZOLE 2 THIONE; 4 (3,5 DIFLUOROBENZYL) 2,4 DIHYDRO [1,2,4]TRIAZOLE 3 THIONE; 4 AMINOOXYMETHYLPHENOL; 4 METHOXY N METHYLPHENETHYLAMINE; 5 (2 AMINOETHYL) 1 (6,8 DIFLUOROCHROMAN 3 YL) 1,3 DIHYDROIMIDAZOLE 2 THIONE; ANTIHYPERTENSIVE AGENT; BIA 5 453; BIS(4 METHYL 1 HOMOPIPERAZINYLTHIOCARBONYL)DISULFIDE; BRL 8242; DIETHYLDITHIOCARBAMIC ACID; DISULFIRAM; DOPAMINE BETA MONOOXYGENASE; DOPAMINE BETA MONOOXYGENASE INHIBITOR; FUSARIC ACID; MDL 43925; NEPICASTAT; PHENETHYLAMINE; PLACEBO; SCH 1059; SKF 02698; TYRAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG DESIGN; DRUG MEGADOSE; DRUG POTENCY; DRUG RESPONSE; DRUG TARGETING; ELECTRON TRANSPORT; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME BINDING; ENZYME METABOLISM; ENZYME SPECIFICITY; ENZYME SUBSTRATE; HUMAN; HYDROXYLATION; HYPERTENSION; NONHUMAN; PROTEIN TARGETING; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; STRUCTURE ANALYSIS;

EID: 65649129671     PISSN: 15734080     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340809787314265     Document Type: Review

References (96)

1. Villafranca, J.J. In Metal Ions in Biology, vol. 3. Spiro, T. G., Ed., Wiley, New York, 1981, 263-289.
2. Stewart, L.C.; Klinman, J.P. Dopamine β-hydroxylase of adrenal chromaffin granules: Structure and function. Annu. Rev. Biochem., 1988, 57, 551-591.
3. Blackburn, N.J. In Bioorganic Chemistry of Copper. Karlin, K.D.; Tyeklár, Z., Eds., Chapman & Hall, New York, 1993, 164-183.
4. Klinman, J.P. Mechanisms whereby mononuclear copper proteins functionalize organic substrates. Chem. Rev., 1996, 96, 2541-2561.
5. Klinman, J.P. The copper-enzyme family of dopamine β-monooxygenase and peptidylglycine α-hydroxylating monooxy-genase: Resolving the chemical pathway for substrate hydroxylation. J. Biol. Chem., 2006, 28 1, 3013-3016.
6. Sirimanne, S.R.; Herman, H.H.; May, S.W. Interaction of dopamine β-mono-oxygenase with substituted imidazoles and pyrazoles. Catalysis and inhibition. Biochem. J., 1987, 242, 227-233.
7. Nakano, T.; Kobayashi, K.; Saito, S.; Fujita, K.; Nagatsu, T. Mouse dopamine β-hydroxylase: Primary structure deduced from the cDNA sequence and exon/intron organization of the gene. Biochem. Biophys. Res. Commun., 1992, 189, 590-599.
8. McMahon, A.; Geertman, R.; Sabban, E.L. Rat dopamine β-hydroxylase: molecular cloning and characterization of the cDNA and regulation of the mRNA by reserpine. J. Neurosci. Res., 1990, 25, 395-404.
9. Wang, N.; Southan, C.; DeWolf, W.E., Jr.; Wells, T.N.; Kruse, L.I.; Leatherbarrow, R.J. Bovine dopamine β-hydroxylase, primary structure determined by cDNA cloning and amino acid sequencing. Biochemistry, 1990, 29, 6466-6474.
10. Wu, H.J.; Parmer, R.J.; Koop, A.H.; Rozansky, D.J.; O'Connor, D.T. Molecular cloning, structure, and expression of dopamine-β-hydroxylase from bovine adrenal medulla. J. Neurochem., 1990, 55, 97-105.
11. Robertson, J.G.; Desai, P.R.; Kumar, A.; Farrington, G.K.; Fitzpatrick, P.F.; Villafranca, J. J. Primary amino acid sequence of bovine dopamine β-hydroxylase. J. Biol. Chem., 1990, 265, 1029-1035.
12. Lewis, E.J.; Allison, S.; Fader, D.; Claflin, V.; Baizer, L. Bovine dopamine β-hydroxylase cDNA. Complete coding sequence and expression in mammalian cells with vaccinia virus vector. J. Biol. Chem., 1990, 265, 1021-1028.
13. Lamouroux, A.; Vigny, A.; Faucon Biguet, N.; Darmon, M.C.; Franck, R.; Henry, J.P.; Mallet, J. The primary structure of human dopamine-β-hydroxylase: Insights into the relationship between the soluble and the membrane-bound forms of the enzyme. EMBO J., 1987, 6, 3931-3937.
14. Kobayashi, K.; Kurosawa, Y.; Fujita, K.; Nagatsu, T. Human dopamine β-hydroxylase gene: Two mRNA types having different 3′-terminal regions are produced through alternative polyadenylation. Nucleic Acids Res., 1989, 17, 1089-1102.
15. Craig, S.P.; Buckle, V.J.; Lamouroux, A.; Mallet, J.; Craig, I.W. Localization of the human dopamine β-hydroxylase (DBH) gene to chromosome 9q34. Cytogenet. Cell Genet., 1988, 48, 48-50.
16. Prigge, S.T.; Mains, R.E.; Eipper, B.A.; Amzel, L.M. New insights into copper monooxygenases and peptide amidation: Structure, mechanism and function. Cell. Mol. Life Sci., 2000, 57, 1236-1259.
17. Dove, S. Picolinic acids as inhibitors of dopamine β-monooxygenase: QSAR and putative binding site. Arch. Pharm. Pharm. Med. Chem., 2004, 337, 645-653.
18. Kamachi, T.; Kihara, N.; Shiota, Y.; Yoshizawa, K. Computational exploration of the catalytic mechanism of dopamine β-monooxygenase: modeling of its mononuclear copper active sites. Inorg. 1Chem., 2005, 44, 4226-4236.
19. Yoshizawa, K.; Kihara, N.; Kamachi, T.; Shiota, Y. Catalytic mechanism of dopamine β-monooxygenase mediated by Cu(III)-oxo. Inorg. Chem., 2006, 45, 3034-3041.
20. Ash, D.E.; Papadopoulos, N.J.; Colombo, G.; Villafranca, J.J. Kinetic and spectroscopic studies of the interaction of copper with dopamine β-hydroxylase. J. Biol. Chem., 1984, 259, 3395-3398.
21. Klinman, J.P.; Krueger, M.; Brenner, M.; Edmondson, D.E. Evidence for two copper atoms/subunit in dopamine β-monooxygenase catalysis. J. Biol. Chem., 1984, 259, 3399-3402.
22. May, S.W.; Phillips, R.S.; Mueller, P.W.; Herman, H.H. Dopamine β-hydroxylase. Comparative specificities and mechanisms of the oxygenation reactions. J. Biol. Chem., 1981, 256, 8470-8475.
23. Blain, I.; Slama, P.; Giorgi, M.; Tron, T.; Réglier, M. Copper-containing monooxygenases: Enzymatic and biomimetic studies of the O-atom transfer catalysis. Rev. Mol. Biotechnol., 2002, 90, 95-112.
24. Bargar, T.M.; Broersma, R.J.; Creemer, L.C.; McCarthy, J.R.; Hornsperger, J.M.; Palfreyman, M.G.; Wagner, J.; Jung, M.J. Unsaturated heterocyclic amines as potent time-dependent inhibitors of dopamine β-hydroxylase. J. Med. Chem., 1986, 29, 315-317.
25. Van der Shoot, J.B.; Crevling, C.R. Substrates and inhibitors of dopamine-β-hydroxylase (DBH). Adv. Drug Res., 1965, 2, 47-88.
26. May, S.W.; Herman, H.H.; Roberts, S.F.; Ciccarello, M.C. Ascorbate depletion as a consequence of product recycling during dopamine β-monooxygenase catalyzed selenoxidation. Biochemistry, 1987, 26, 1626-1633.
27. Klinman, J.P.; Krueger, M. Dopamine β-hydroxylase: Activity and inhibition in the presence of β-substituted phenethylamines. Biochemistry, 1982, 21, 67-75.
28. May, S.W.; Mueller, P.W.; Padgette, S.R.; Herman H.H.; Phillips, R.S. Dopamine-β-hydroxylase: Suicide inhibition by the novel olefinic substrate, 1-phenyl-1-aminomethylethene. Biochem. Biophys. Res. Commun., 1983, 110, 161-168.
29. Padgette, S.R.; Wimalasena, K.; Herman, H.H.; Sirimanne, S.R.; May, S.W. Olefin oxygenation and N-dealkylation by dopamine β-monooxygenase: catalysis and mechanism-based inhibition. Biochemistry, 1985, 24, 5826-5839.
30. Wimalasena, K.; Alliston, K.R. 1-(2-Aminoethyl)-1,4-cyclohexadiene: A probe to examine the chemistry and energetics of the C-H bond cleavage in dopamine β-monooxygenase catalysis. J. Am. Chem. Soc., 1995, 117, 1220-1224.
31. Scott, R.A.; Sullivan, R.J.; DeWolf, W.E., Jr.; Dolle, R.E.; Kruse, L.I. The copper sites of dopamine β-hydroxylase: An X-ray absorption spectroscopic study. Biochemistry, 1988, 27, 5411-5417.
32. Blackburn, N.J.; Hasnain, S.S.; Pettingill, T.M.; Strange, R.W. Copper K-extended x-ray absorption fine structure studies of oxidized and reduced dopamine β-hydroxylase. Confirmation of a sulfur ligand to copper(I) in the reduced enzyme. J. Biol. Chem., 1991, 266, 23120-23127.
33. McCracken, J.; Desai, P.R.; Papadopoulos, N.J.; Villafranca, J.J.; Peisach, J. Electron spin-echo studies of the copper(II) binding sites in dopamine β-hydroxylase. Biochemistry, 1988, 27, 4133-4137.
34. Blackburn, N.J.; Concannon, M.; Shahiyan, S.K.; Mabbs, F.E.; Collison, D. Active site of dopamine β-hydroxylase. Comparison of enzyme derivatives containing four and eight copper atoms per tetramer using potentiometry and EPR spectroscopy. Biochemistry, 1988, 27, 6001-6008.
35. Brenner, M.C.; Murray, C.J.; Klinman, J.P. Correlation of copper valency with product formation in single turnovers of dopamine β-monooxygenase. Biochemistry, 1989, 28, 4664-4670.
36. Brenner, M.C.; Klinmam, J.P. Rapid freeze- and chemical-quench studies of dopamine β-monooxygenase: Comparison of pre-steady-state and steady-state parameters. Biochemistry, 1989, 28, 4656-4664.
37. Prigge, S.T.; Kolhekar, A.S.; Eipper, B.A.; Mains, R.E.; Amzel, L.M. Amidation of bioactive peptides: The structure of peptidylglycine α-hydroxylating monooxygenase. Science, 1997, 278, 1300-1305.
38. Prigge, S.T.; Kolhekar, Eipper, B.A.; Mains, R.E.; Amzel, L.M. Substrate-mediated electron transfer in peptidylglycine α-hydroxylating monooxygenase. Nat. Struct. Biol., 1999, 6, 976-983.
39. Prigge, S.T.; Eipper, B.A.; Mains, R.E.; Amzel, L.M. Dioxygen binds end-on to mononuclear copper in a precatalytic enzyme complex. Science, 2004, 304, 864-867.
40. Evans, J.P.; Ahn, K.; Klinman, J.P. Evidence that dioxygen and substrate activation are tightly coupled in dopamine β-monooxygenase. Implications for the reactive oxygen species. J. Biol. Chem., 2003, 278, 49691-49698.
41. Wimalasena, K.; Dharmasena, S.; Wimalasena, D.S.; Hughbanks-Wheaton, D.K. Reduction of dopamine β-monooxygenase. A unified model for apparent negative cooperativity and fumarate activation. J. Biol. Chem., 1996, 271, 26032-26043.
42. Wimalasena, K.; Dharmasena, S.; Wimalasena, D.S. N,N,N′,N′-tetramethyl-1,4-phenylenediamine: A facile electron donor and chromophoric substrate for dopamine β-monooxygenase. Biochem. Biophys. Res. Commun., 1991, 175, 920-927.
43. Wimalasena, K.; Wimalasena, D.S. Ascorbate based novel high affinity alternate reductants and competitive inhibitors of dopamine β-monooxygenase. Biochem. Biophys. Res. Commun., 1994, 200, 113-119.
44. Freeman, J.C.; Villafranca, J.J. Redox cycling of enzyme-bound copper during peptide amidation. J. Am. Chem. Soc., 1993, 115, 4923-4924.
45. Karlin, K.D.; Kaderli, S.; Zuberbuhler, A.D. Kinetics and thermodynamics of copper(I)/dioxygen interaction. Acc. Chem. Res., 1997, 30, 139-147.
46. Casella, L.; Gullotti, M.; Bartosek, M.; Pallanza, G.; Laurenti, E. Model monooxygenase reactivity by binuclear two-coordinate copper(I) complexes extends to new ligand systems containing nitrogen and sulphur donors. J. Chem. Soc., Chem. Comm., 1991, 1235-1237.
47. Gherman, B.F.; Heppner, D.E.; Tolman, W.B.; Cramer, C.J. Models for dioxygen activation by the CuB site of dopamine β-monooxygenase and peptidylglycine β-hydroxylating monooxygenase. J. Biol. Inorg. Chem., 2005, 11, 197-205.
48. 3]: antiferromagnetic coupling versus covalent delocalization. J. Am. Chem. Soc., 2003, 125, 466-474.
49. 2+ (tpy = 2,2′:6,2″-terpyridine) by ferric ions in aqueous glasses at 77 K. J. Am. Chem. Soc., 2000, 122, 8187-8191.
50. Tezcan, F.A.; Crane, B.R.; Winkler, J.R.; Gray, H.B. Electron tunneling in protein crystals. Proc. Natl. Acad. Sci. USA, 2001, 98, 5002-5006.
51. Reedy, B.J.; Murthy, N.N.; Karlin, K.D.; Blackburn, N.J. Isocyanides as ligand-directed indicators of Cu(I) coordination in copper proteins. Probing the inequivalence of the Cu(I) centers in reduced dopamine-β-monooxygenase. J. Am Chem. Soc., 1995, 117, 9826-9831.
52. Jaron, S.; Blackburn, N.J. Does superoxide channel between the copper centers in peptidylglycine monooxygenase? A new mechanism based on carbon monoxide reactivity. Biochemistry, 1999, 38, 15086-15096.
53. Bell, J.; Meskini, R.E.; D'Amato, D.; Mains, R.E.; Eipper, B.A. Mechanistic investigation of peptidylglycine α-hydroxylating monooxygenase via intrinsic tryptophan fluorescence and mutagenesis. Biochemistry, 2003, 42, 7133-7142.
54. Chen, P.; Salomon, E.I. Oxygen activation by the noncoupled binuclear copper site in peptidylglycine α-hydroxylating monooxygenase. Reaction mechanism and role of the noncoupled nature of the active site. J. Am. Chem. Soc., 2004, 126, 4991-5000.
55. Goldstein, M.; Anagnoste, B.; Lauber, E.; McKereghan, M. R. Inhibition of dopamine-β-hydroxylase by disulfiram. Life Sci., 1964, 3, 763-767.
56. Lippmann, W.; Lloyde, K. Dopamine-β-hydroxylase inhibition by dimethyldithiocarbamate and related compounds. Biochem. Pharmacol., 1969, 18, 2507-2516.
57. Corrodi, H.; Fuxe, K.; Hamberger, B.; Ljungdahl, A. Studies on central and peripheral noradrenaline neurons using a new dopamine-β-hydroxylase inhibitor. Eur. J. Pharmacol., 1970, 12, 145-155.
58. Johnson, G.A.; Boukma, S. J.; Kim, E. G. In vivo inhibition of dopamine β-hydroxylase by 1-phenyl-3-(2-thiazolyl)-2-thiourea (U-14,624). J. Pharmacol. Exp. Ther., 1970, 171, 80-87.
59. Claxton, I.M.; Palfreyman, M.G.; Poyser, R.H.; Whiting, R.L. BRL 8242 (2-[2-benzimidazolyl]-amino-2-imidazoline dihydrochloride), a new inhibitor of dopamine-β-hydroxylase with antihypertensive activity. Eur. J. Pharmacol., 1976, 37, 179-188.
60. Hidaka, H. Fusaric (5-butylpicolinic) acid, an inhibitor of dopamine β-hydroxylase, affects serotonin and noradrenaline. Nature, 1971, 231, 54-55.
61. Nagatsu, T.; Hidaka, H.; Kuzuya, H.; Takeya, K.; Umezawa, H. Inhibition of dopamine β-hydroxylase by fusaric acid (5-butylpicolinic acid) in vitro and in vivo. Biochem. Pharmacol., 1970, 19, 35-44.
62. Korduba, C.A.; Veals, J.; Wohl, A.; Symchowicz, S.; Tabachnick, I.I.A. SCH 10595, an effective dopamine-β-hydroxylase inhibitor and a hypotensive agent. J. Pharm. Exp. Ther., 1973, 184, 671-677.
63. Piesche, L.; Hilse, H.; Oehlke, J.; Schrotter, E.; Oehme, P. Substituted picolinic acids as DBH inhibitors. Inhibition of dopamine β-hydroxylase and antihypertensive action. Pharmazie, 1983, 38, 335-338.
64. Kruse, L.L.; Kaiser, C.; DeWolf, W.E., Jr.; Frazee, J.S.; Erickson, R.W.; Ezekiel, M.; Ohlstein, E.H.; Ruffolo, R.R., Jr.; Berkowitz, B.A. Substituted 1-benzylimidazole-2-thiols as potent and orally active inhibitors of dopamine β-hydroxylase. J. Med. Chem., 1986, 29, 887-889.
65. Kruse, L.I.; Kaiser, C.; DeWolf, W.E., Jr.; Frazee, J.S.; Garvey, E.; Hilbert, E.L.; Faulkner, W.A.; Flaim, K.E.; Sawyer, J.L.; Berkowitz, B.A. Multisubstrate inhibitors of dopamine β-hydroxylase. 1. Some 1-phenyl and 1-phenyl-bridged derivatives of imidazole-2-thione. J. Med. Chem., 1986, 29, 2465-2472.
66. Kruse, L.I.; Kaiser, C.; DeWolf, W.E., Jr.; Frazee, J.S.; Ross, S.T.; Wawro, J.; Wise, M.; Flaim, K.E.; Sawyer, J.L.; Erickson, R.W.; Ezekiel, M.; Ohlstein, E.H.; Berkowitz, B.A. Multisubstrate inhibitors of dopamine β-hydroxylase. 2. Structure-activity relationships at the phenethylamine binding site. J. Med. Chem., 1987, 30, 486-494.
67. Ross, S.T.; Kruse, L.I.; Ohlstein, E.H.; Erickson, R.W.; Ezekiel, M.; Flaim, K.E.; Sawyer, J.L.; Berkowitz, B.A. Inhibitors of dopamine β-hydroxylase. 3. Some 1-(pyridylmethyl)imidazole-2-thiones. J. Med. Chem., 1987, 30, 1309-1313.
68. McCarthy, J.R.; Matthews, D.P.; Broersma, R.J.; McDermott, R.D.; Kastner, P.R.; Hornsperger, J.-M.; Demeter, D.A.; Weintraub, H.J.R.; Whitten, J.P. 1-(Thienylalkyl)imidazole-2(3H)-thiones as potent competitive inhibitors of dopamine β-hydroxylase. J. Med. Chem., 1990, 33, 1866-1873.
69. Kruse, L.I.; DeWolf, W.E., Jr.; Chambers, P.A.; Goodhart, P.J. Design and kinetic characterization of multisubstrate inhibitors of dopamine β-hydroxylase. Biochemistry, 1986, 25, 7271-7278.
70. Burke, B.J.; Hopfinger, A.J. 1-(Substituted-benzyl)imidazole-2(3H)-thione inhibitors of dopamine β-hydroxylase. J. Med. Chem., 1990, 33, 274-281.
71. Demeter, D.A.; Weintraub, H.J.R.; Knittel, J.J. The local minima method (LMM) of pharmacophore determination: A protocol for predicting the bioactive conformation of small, conformationally flexible molecules. J. Chem. Inf. Comput. Sci., 1998, 38, 1125-1136.
72. Martinez, G.R.; Gooding, O.W.; Repke, D.B.; Teitelbaum, P.J.; Walker, K.A.M.; Whiting, R.L. US Patent No. 5,538,988, 1996.
73. Stanley, W.C.; Li, B.; Bonhaus, D.W.; Johnson, L.G.; Lee, K.; Porter, S.; Walker, K; Martinez, G.; Eglen, R.M.; Whiting, R.L.; Hedge, S.S. Catecholamine modulatory effects of nepicastat (RS-5560-197), a novel, potent and selective inhibitor of dopamine β-hydroxylase. Br. J Pharmacol., 1997, 121, 1803-1809.
74. Beliaev, A.; Learmonth, D.A.; Soares-da-Silva, P. Synthesis and biological evaluation of novel, peripherally selective chromanyl imidazolethione-based inhibitors of dopamine β-hydroxylase. J. Med. Chem., 2006, 49, 1191-1197.
75. Kruse, L.I.; Kaiser, C.; DeWolf, W.E.; Finkelstein, J.A.; Frazee, J.S.; Hilbert, E.L.; Ross, S.T.; Flaim, K.E.; Sawyer, J.L. Some benzyl-substituted imidazoles, triazoles, tetrazoles, pyridinethiones, and structural relatives as multisubstrate inhibitors of dopamine β-hydroxylase. 4. Structure-activity relationships at the copper binding site. J. Med. Chem., 1990, 33, 781-789.
76. Wimalasena, K.; Wimalasena, D.S.; Dharmasena, S.; Haines, D.C.; Alliston, K.R. Chiral multisubstrate inhibitors of dopamine β-monooxygenase: Evidence for dual modes of interaction. Biochemistry, 1997, 36, 7144-7153.
77. Dharmasena, S.; Wimalasena, D.S.; Wimalasena, K. A slow-tight binding inhibitor of dopamine β-monooxygenase: A transition state analogue for the product release step. Biochemistry, 2002, 41, 12414-12420.
78. Colombo, G.; Villafranca, J.J. An acetylenic mechanism-based inhibitor of dopamine β-hydroxylase. J. Biol. Chem., 1984, 259, 15017-15020.
79. Colombo, G.; Rajashekhar, B.; Giedroc, D.P.; Villafranca, J.J. Mechanism-based inhibitors of dopamine β-hydroxylase: Inhibition by 2-bromo-3-(p-hydroxyphenyl)-1-propene. Biochemistry, 1984, 23, 3590-3598.
80. Bossard, M.J.; Klinman, J.P. Mechanism-based inhibition of dopamine beta-monooxygenase by aldehydes and amides. J. Biol. Chem., 1986, 261, 16421-16427.
81. Kruse, L.I.; DeWolf, C.K.W.E., Jr.; Chambers, P.A.; Goodhart, P.J.; Ezekiel, M.; Ohlstein, E.H. Beta-substituted phenethylamines as high-affinity mechanism-based inhibitors of dopamine β-hydroxylase. J. Med. Chem., 1988, 31, 704-706.
82. Eydoux, F.; Chlenov, M. A.; Réglier, M. Synthesis of indane derivatives as mechanism-based inhibitors of dopamine β-hydroxylase. Bioorg. Med. Chem. Lett., 1995, 5, 941-944.
83. Terazawa, F.; Kameyama, M. The clinical trial of a new hypotensive agent, "fusaric acid (5-butylpicolinic acid)": The preliminary report. Jpn. Circulation J., 1971, 35, 339-357.
84. Hedge, S.S.; Friday, K.F. Dopamine β-hydroxylase inhibition: A novel sympatho-modulatory approach for the treatment of congestive heart failure. Curr. Pharm. Des., 1998, 4, 469-479.
85. Igreja, B., Wright, L.C.; Soares-da-Silva, P. Sustained antihypertensive effects of a selective peripheral dopamine-β-hydroxylase inhibitor. Hypertension, 2007, 50, e133.
86. Herman, H.H.; Pollock, S.H.; Fowler, L.C.; May, S.W. Demonstration of the potent antihypertensive activity of phenyl-2-aminoethyl sulfides. J. Cardiovasc. Pharmacol., 1988, 11, 501-510.
87. Pollock, S.H.; Reichbaum, M.I.; Colbert, J.C.; Husain, P.A.; Holbrook, J.M.; Ogonowski, A.A.; Khlief, J.S.; May, S.W. The oral antihypertensive activity of the methylated derivatives of phenyl-2-aminoethyl sulfide. J. Pharm. Exp. Ther., 1993, 265, 1113-1117.
88. Pollock, S.H.; Herman, H.H.; Fowler, L.C.; Edwards, A.S.; Evans, C.-O.; May, S.W. Demonstration of the antihypertensive activity of phenyl-2-aminoethyl selenide. J. Pharm. Exp. Ther., 1988, 246, 227-234.
89. Parmley, W.W. Neuroendocrine changes in heart failure and their clinical relevance. Clin. Cardiol., 1995, 18, 440-445.
90. Levine, T.B.; Francis, G.S.; Goldsmith, S.R.; Simon, A.B.; Cohn, J.N. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. Am. J. Cardiol., 1982, 49, 1659-1666.
91. Leimbach, W.N., Jr.; Wallin, B.G.; Victor, R.G.; Aylward, P.E.; Sundlof, G.; Mark, A.L. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation, 1986, 73, 913-919.
92. Hasking, G.J.; Esler, M.D.; Jennings, G.L.; Burton, D.; Johns, J.A.; Korner, P.I. Norepinephrine spillover to plasma in patients with congestive heart failure: Evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation, 1986, 73, 615-621.
93. Cohn, J.N.; Levine, T.B.; Olivari, M.T.; Garberg, V.; Lura, D.; Francis, G.S.; Simon, A.B.; Rector, T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N. Engl. J. Med., 1984, 311, 819-823.
94. Benedict, C.R.; Shelton, B.; Johnstone, D.E.; Francis, G.; Greenberg, B.; Konstam, M.; Probstfield, J.L.; Yusuf, S. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators. Circulation, 1996, 94, 690-697.
95. Pfeffer, M.A.; Stevenson, L.W. Beta-adrenergic blockers and survival in heart failure. N. Engl. J. Med., 1996, 334, 1396-1397.
96. Sabbah, H.N.; Stanley, W.C.; Sharov, V.G.; Mishima, T.; Tanimura, M.; Benedict, C.R.; Hedge, S.; Goldstein, S. Effects of dopamine β-hydroxylase inhibition with nepicastat on the progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure. Circulation, 2000, 102, 1990-1995.